LAG-3 Blockade with Relatlimab (BMS-986016) Restores Anti-Leukemic Responses in Chronic Lymphocytic Leukemia.

LAG-3 levels were also elevated in total CD3+ T lymphocytes and CD8+ effector T cells, but it did not reach statistical significance in CD4+ T cells (MFI: 213.8 ± 16.7 vs. 151.3 ± 8.3, p = 0.02, 290.1 ± 23.5 vs. 188.7 ± 14.2, p = 0.005 and 176.7 ± 17.78 vs. 132.9 ± 6.3, p = ns, respectively) ( Figure 4 A,D).

also in 111,027 other papers